Received Aug 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y013565 | OT |
No additional AE; Caller reported patient received 1st does of GARDASIL 9 on 6/21/2022 and 2nd dose on 8/1/2025. Product information reflects Lot and expiration date of 2nd dose. No other information provided. No additional AE/PQC reported.; This spontaneous report was received from a Medical Assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not provided. On 21-Jun-2022, the patient started prophylactic therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), dose number 1, administered by unknown route (lot # and expiration date were not reported). On 08-Jan-2025, the patient was vaccinated with the 2nd dose of Human Papillomavirus 9-valent Vaccine, Recombinant (lot #Y013565, expiration date: 01-Feb-2027), 0.5 mL, administered by intramuscular route for prophylaxis (Inappropriate schedule of product administration). No additional adverse events. At the reporting time, the outcome of the events was unknown. The action taken with the suspect vaccine was not applicable.